Healthequity (HQY) Price Target Raised to $62.00 at Chardan Capital

Healthequity (NASDAQ:HQY) had its price objective upped by Chardan Capital from $58.00 to $62.00 in a report published on Wednesday morning. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently commented on HQY. Zacks Investment Research cut shares of Healthequity from a buy rating to a hold rating in a research note on Wednesday, November 15th. BidaskClub cut shares of Healthequity from a hold rating to a sell rating in a research note on Wednesday, October 18th. Cantor Fitzgerald reissued a buy rating and issued a $56.00 price objective on shares of Healthequity in a research note on Tuesday, September 5th. Robert W. Baird reissued a hold rating on shares of Healthequity in a research note on Thursday, September 21st. Finally, Oppenheimer restated a buy rating and issued a $61.00 target price on shares of Healthequity in a report on Wednesday, September 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Healthequity presently has a consensus rating of Buy and an average target price of $58.33.

Healthequity (NASDAQ HQY) traded down $2.49 during trading hours on Wednesday, hitting $46.00. 1,624,500 shares of the stock were exchanged, compared to its average volume of 527,424. Healthequity has a fifty-two week low of $37.62 and a fifty-two week high of $55.31. The firm has a market cap of $2,933.10, a PE ratio of 69.27, a PEG ratio of 2.13 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.04. Healthequity had a net margin of 21.08% and a return on equity of 15.03%. The business had revenue of $56.80 million for the quarter, compared to analysts’ expectations of $55.27 million. During the same period in the prior year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 31.0% on a year-over-year basis. sell-side analysts forecast that Healthequity will post 0.7 earnings per share for the current fiscal year.

In other news, major shareholder Berkley Capital, Llc sold 373,500 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $53.21, for a total transaction of $19,873,935.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Ashley Dreier sold 10,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $50.97, for a total transaction of $509,700.00. Following the transaction, the vice president now owns 15,652 shares in the company, valued at $797,782.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,743,212 shares of company stock worth $91,145,351. 29.00% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC raised its holdings in Healthequity by 6.0% in the first quarter. Teachers Advisors LLC now owns 79,893 shares of the company’s stock valued at $3,391,000 after buying an additional 4,542 shares during the period. Dimensional Fund Advisors LP raised its holdings in Healthequity by 38.5% in the first quarter. Dimensional Fund Advisors LP now owns 377,919 shares of the company’s stock valued at $16,042,000 after buying an additional 104,960 shares during the period. Renaissance Technologies LLC purchased a new position in Healthequity in the first quarter valued at approximately $1,426,000. Creative Planning raised its holdings in Healthequity by 94.4% in the second quarter. Creative Planning now owns 3,274 shares of the company’s stock valued at $163,000 after buying an additional 1,590 shares during the period. Finally, Aperio Group LLC raised its holdings in Healthequity by 28.2% in the second quarter. Aperio Group LLC now owns 12,773 shares of the company’s stock valued at $636,000 after buying an additional 2,806 shares during the period. Institutional investors and hedge funds own 98.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Healthequity (HQY) Price Target Raised to $62.00 at Chardan Capital” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/12/07/healthequity-hqy-price-target-raised-to-62-00-at-chardan-capital.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply